Dr. David S. Schrump, MD, MBA, FACS

Expert Publications

• NY-ESO-1 may be a potential target for lung cancer immunotherapy.
• Sequence-dependent enhancement of paclitaxel toxicity in non-small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin.
• Antisense to SV40 early gene region induces growth arrest and apoptosis in T-antigen-positive human pleural mesothelioma cells.
• Strategies for molecular intervention in esophageal cancers and their precursor lesions.
• Ultrasound and sestamibi scan as the only preoperative imaging tests in reoperation for parathyroid adenomas.
• Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin.
• Induction of MAGE-3 expression in lung and esophageal cancer cells.
• Strategies to circumvent SV40 oncoprotein expression in malignant pleural mesotheliomas.
• Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1.
• The epidermal growth factor receptor-STAT pathway in esophageal cancer.
• Targets for molecular intervention in multistep pulmonary carcinogenesis.
• Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis.
• Induction of apoptosis in malignant pleural mesothelioma cells by activation of the Fas (Apo-1/CD95) death-signal pathway.
• Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228.
• Virtual bronchoscopy for evaluation of malignant tumors of the thorax.

Media Releases

Get to know Cardiothoracic Surgeon Dr. David S. Schrump, who serves patients in Bethesda, Maryland.

Dr. Schrump, a board-certified cardiothoracic surgeon, serves as the Chief of the Thoracic Surgery Branch at the National Cancer Institute Center for Cancer Research in Bethesda, Maryland. 

The Thoracic Surgery Branch conducts laboratory research pertaining to mechanisms of initiation and progression of thoracic malignancies; translates results of laboratory research to clinical protocols examining novel strategies to improve detection, diagnosis, and treatment of these neoplasms; mentors future leaders in thoracic surgical oncology and translational cancer research; and provides comprehensive clinical support for all patients with thoracic surgical issues at the NIH Clinical Center.

As Chief of the Branch, Dr. Schrump oversees clinical and translational research pertaining to thoracic malignancies, including the development of innovative molecular approaches to the diagnosis and treatment of these neoplasms. He has pioneered the development of epigenetic therapies for thoracic cancers. Using unique in vitro models and correlative experiments with surgical specimens, he has characterized epigenetic responses to tobacco carcinogens, and identified novel therapeutic targets in lung and esophageal cancers and pleural mesotheliomas. His clinical protocols have demonstrated that chromatin remodeling agents simultaneously induce growth arrest and augment immunogenicity of thoracic malignancies; these efforts have provided rationale for combining epigenetic regimens with immunotherapies for these neoplasms. Results of his laboratory and clinical efforts have been presented at numerous international meetings and have been published in top-tier scientific and thoracic surgery journals.

A 1983 graduate of the University of Connecticut School of Medicine, Dr. Schrump completed his residency in general surgery at the University of Chicago, as well as a 3-year research fellowship in human cancer immunology at Memorial Sloan-Kettering Cancer Center. Following completion of his residency in thoracic surgery at the University of Michigan in 1993, he was appointed to the cardiothoracic surgery faculty at M.D. Anderson Cancer Center. In 1997, he was appointed Head of Thoracic Oncology, Surgery Branch, NCI. He received NIH tenure in 2006. Wanting to further his education, Dr. Schrump went on to receive his Master of Business Administration degree in Health Services Management from the Carey School of Business, Johns Hopkins University in 2009. He is a member of the American Association for Thoracic Surgery, the Society of Thoracic Surgeons, the John Alexander Society, and the International Association for the Study of Lung Cancer.

A Fellow of the American College of Surgeons, the doctor is board-certified in thoracic surgery by the American Board of Thoracic Surgery, an American surgical organization devoted to surgery of the chest. Dr. Schrump is internationally renowned for his expertise pertaining to surgical management of complex thoracic malignancies including lung and esophageal cancers, malignant pleural mesothelioma, chest wall sarcomas, and pulmonary metastases.

Cardiothoracic surgery is the field of medicine involved in the surgical treatment of organs inside the thorax. Cardiothoracic surgeons are medical doctors who specialize in surgical procedures inside the thorax, which may involve the heart, lungs, esophagus, and other organs in the chest. Alongside performing surgery, they also diagnose and treat diseases of these organs. 

Recommended Articles

• How Does your Triglyceride Level Affect You?

  Triglycerides are produced as a product of breakdown of fats. It is also produced from carbohydrates to be stored as energy. Triglycerides are generally stored in fat cells and released when needed.The healthy range or normal level of triglycerides in the body is less than 150 milligrams per...

• What Is an Arrhythmia?

  An arrhythmia is the violations of the frequency, rhythm, and sequence of heart contractions.Why do arrythmias occur?...

• Complications of Myocardial Infarction

  Complications can be divided according to different factors:...

• Different Types of Heart Doctors Explained

  IntroductionDoctors who specialize in the diagnosis and treatment of conditions or diseases of the cardiovascular system (the heart and blood vessels) are called heart doctors or cardiologists. These specialists are trained to identify, treat, and help prevent heart issues. There are also different...

• Are There Benign and Malignant Tumors of the Heart?

  It is a well-known fact that in the body, in various tissues due to various reasons, neoplasms sometimes appear in the form of tumor growths. The heart is not an exception. The tumor growth can be benign and malignant. Therefore, there are two types of the heart tumors.Benign tumors These do not...

• Atypical Forms of Myocardial Infarction

  Atypical myocardial infarction often occurs in older patients with a pronounced cardiosclerosis, circulatory failure, and often with people who have a history of heart attacks.The symptoms may confuse you, or make you think that they are not associated with the heart.Usually, atypical manifestations...